初治HIV成人Doravirine方案与治疗相关体重增加:Opti-DOR随机临床试验
Opti-DOR非劣效随机试验纳入600例未治HIV成人,比较Doravirine+拉米夫定+TDF与Dolutegravir+恩曲他滨+TAF。48周病毒抑制非劣效(89.0% vs 90.7%,差-1.7个百分点,95%CI -6.6~3.1),Doravirine组体重增加更少(中位3.0 kg vs 5.0 kg,差-2.0 kg,95%CI -3.0~-1.0,P<.001),但髋和脊柱骨密度下降更多。
要点
- Doravirine+拉米夫定+TDF组48周病毒抑制非劣效于Dolutegravir+恩曲他滨+TAF组。
- Doravirine组中位体重增加3.0 kg,低于Dolutegravir组的5.0 kg。
- Doravirine组髋和脊柱骨密度下降幅度大于Dolutegravir组。
核心结论
- 在 predominantly Black African 初治成人中,Doravirine+拉米夫定+TDF方案48周病毒抑制非劣效于Dolutegravir+恩曲他滨+TAF方案。
- Doravirine+拉米夫定+TDF方案与更少的体重增加相关。
研究设计与样本
- 开放标签、非劣效随机临床试验,在南非2个中心开展,2023年10月至2025年3月招募。
- 纳入600例未治HIV成人(≥18岁),HIV RNA>500 copies/mL且基线无高水平Doravirine耐药。
- 干预为每日一次Doravirine 100 mg+拉米夫定300 mg+TDF 300 mg(n=299)或Dolutegravir 50 mg+恩曲他滨200 mg+TAF 25 mg(n=301)。
主要发现
- 48周病毒抑制(HIV RNA<50 copies/mL):Doravirine组266例(89.0%)vs Dolutegravir组273例(90.7%),组间差-1.7个百分点(95%CI -6.6~3.1),满足预设非劣效界值-10个百分点。
- 中位体重增加:Doravirine组3.0 kg vs Dolutegravir组5.0 kg,组间差-2.0 kg(95%CI -3.0~-1.0 kg;P<.001)。
- 髋骨密度中位变化:Doravirine组-2.1%(IQR -4.1%~-0.5%)vs Dolutegravir组-0.5%(IQR -1.9%~1.2%);脊柱骨密度中位变化:Doravirine组-3.2%(IQR -5.4%~-0.8%)vs Dolutegravir组-1.3%(IQR -3.2%~0.8%),组间比较均P<.001。
- Doravirine组9例病毒学失败者中7例出现Doravirine耐药;其中6例中5例换用Dolutegravir方案后实现病毒抑制,1例失访。
- 严重不良事件和死亡(n=2)不常见,且被认为与治疗无关。
关键数值与推荐
- 主要终点非劣效界值为-10个百分点。
- 48周病毒抑制率组间差-1.7个百分点(95%CI -6.6~3.1),达到非劣效。
- 体重增加组间差-2.0 kg(95%CI -3.0~-1.0 kg;P<.001)。
- 髋和脊柱骨密度组间比较均P<.001。
临床怎么用
- 对于初治HIV成人,Doravirine+拉米夫定+TDF可作为病毒抑制非劣效且体重增加更少的选项。
- 选择该方案时需关注骨密度下降风险,并监测病毒学失败及Doravirine耐药的发生。
局限性
- 开放标签设计。
- 研究人群主要为 Black African 成人,外推需谨慎。
- 随访至48周,长期体重和骨密度影响未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antiretroviral therapy (ART), particularly regimens containing tenofovir alafenamide with dolutegravir or bictegravir, is associated with substantial weight gain, potentially exacerbating cardiometabolic risk in people with HIV. OBJECTIVE: To determine whether a regimen with doravirine, lamivudine, and tenofovir disoproxil fumarate results in less weight gain than a regimen with dolutegravir, emtricitabine, and tenofovir alafenamide while maintaining noninferior viral suppression. DESIGN, SETTING, AND PARTICIPANTS: Open-label, noninferiority randomized clinical trial including ART-naive adults (≥18 years of age) with an HIV RNA level greater than 500 copies/mL and no detectable baseline, high-level doravirine resistance. The study was conducted at 2 South African sites and individuals were recruited between October 2023 and March 2025. The final participant visit occurred in February 2026. INTERVENTIONS: A once-daily regimen with 100 mg of doravirine, 300 mg of lamivudine, and 300 mg of tenofovir disoproxil fumarate (n = 299) or 50 mg of dolutegravir, 200 mg of emtricitabine, and 25 mg of tenofovir alafenamide (n = 301). MAIN OUTCOMES AND MEASURES: The primary outcome was viral suppression (HIV RNA level <50 copies/mL) at week 48 (prespecified noninferiority margin of -10 percentage points). The key secondary outcomes included changes in body weight, treatment-associated effects on body composition, and safety and adverse events. RESULTS: Among 600 participants, 597 (99.5%) were Black African, 413 (68.8%) were assigned female at birth, and the median age was 34 years (IQR, 28-41). At week 48, 266 participants (89.0%) in the doravirine, lamivudine, and tenofovir disoproxil fumarate group achieved viral suppression (HIV RNA level <50 copies/mL) vs 273 participants (90.7%) in the dolutegravir, emtricitabine, and tenofovir alafenamide group (between-group difference, -1.7 percentage points [95% CI, -6.6 to 3.1], meeting the prespecified noninferiority margin of -10 percentage points). The median weight gain was 3.0 kg in the doravirine, lamivudine, and tenofovir disoproxil fumarate group vs 5.0 kg in the dolutegravir, emtricitabine, and tenofovir alafenamide group (between-group difference, -2.0 kg [95% CI, -3.0 to -1.0 kg]; P < .001). Among participants in the doravirine, lamivudine, and tenofovir disoproxil fumarate group, the median change in hip bone mineral density (BMD) was -2.1% (IQR, -4.1% to -0.5%) and was -3.2% (IQR, -5.4% to -0.8%) for spine BMD vs -0.5% (IQR, -1.9% to 1.2%) for hip BMD and -1.3% (IQR, -3.2% to 0.8%) for spine BMD with dolutegravir, emtricitabine, and tenofovir alafenamide (P < .001 for each between-group comparison). Resistance to doravirine emerged among 7 of 9 participants experiencing virologic failure in the doravirine, lamivudine, and tenofovir disoproxil fumarate group. Of these 7 participants, 5 of 6 achieved viral suppression after switching to dolutegravir-based therapy and 1 was lost to follow-up. Serious adverse events and deaths (n = 2) were infrequent and not considered treatment-related. CONCLUSIONS AND RELEVANCE: Among predominantly Black African adults initiating ART, a regimen with doravirine, lamivudine, and tenofovir disoproxil fumarate was noninferior to a regimen with dolutegravir, emtricitabine, and tenofovir alafenamide for 48-week viral suppression and was associated with less weight gain. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05924438.
引用
- Woods J, Lebina L, Möller K, et al. Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial. JAMA. 2026. PMID: 42536019. doi:10.1001/jama.2026.14762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。